UNSPSC 51182301: Somatrem

This classification denotes a pituitary agent with the molecular formula C995H1537N263O301S8, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier CU8D464EDW, more generally known as somatrem. European Medicines Agency schedules somatrem in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10583MIG. The term SOMATREM is an International Non-Proprietary Name or INN. SOMATREM is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix.

Most nations schedule somatrem under HS 29371100 and SITC 54154. As of Q4 2014, SOMATREM remains the US FDA Preferred Term for this commodity. Somatrem bears US NLM identifiers UMLS ID C0143083 and NCI Concept Code C66556. SMILES: NONE.

UNSPSC 51182301 Somatrem is a Commodity code covering pharmaceutical products supplied through cooperative purchasing arrangements to state and local government health facilities. State and local governments procure somatrem and related generic pharmaceuticals through multistate cooperative purchasing vehicles, with recent activity centered on establishing blanket supply agreements rather than one-time transactions. The primary issuing body pattern involves state departments of administration and health systems using cooperative purchasing alliances to aggregate demand across multiple jurisdictions and establish preferred-vendor relationships with pharmaceutical manufacturers. Supply agreements typically require manufacturers to maintain relationships with authorized wholesalers, certify compliance with Good Manufacturing Practices and Drug Supply Chain Security Act requirements, and offer flexible pricing structures across multiple formats (fixed price, net pricing, WAC-minus configurations). Vendors must carry substantial liability insurance, maintain product availability with minimum shelf-life requirements, and accept administrative fees and performance penalty provisions.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP for generic multi-source pharmaceuticals and OTC products on January 20, 2026, with a response deadline of March 26, 2026, covering participating state and local government facilities in Minnesota, Oregon, and other member jurisdictions. The solicitation (S1070000015802) emphasizes price competitiveness (weighted at 75 percent of evaluation criteria), with remaining weight distributed across fixed pricing, administrative compliance, EDI capability, and willingness to accept a 3 percent administrative fee. Award was expected to be finalized by May 15, 2026, with resulting contracts effective July 1, 2026 for an initial two-year term with optional extensions. No specific dollar value or set-aside designations were disclosed in the available documentation.